The Use of Ondansetron for the Treatment of Nausea in Dogs With Vestibular Syndrome

Foth, S.; Meller, S.; Kenward, Hannah; Elliot, Jessica; Pelligand, Ludovic; Volk, H. A.

doi:10.21203/rs.3.rs-279349/v1

Cited by 2 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results have been observed in other experimental studies, such as in dogs with renal disease or when used against preoperative nausea 19,22,35 . After promising results when using ondansetron against vestibular nausea, 28 our current study emphasizes further the potential for the use of ondansetron to treat nausea resulting from vestibular syndrome in dogs.…”

Section: Discussionsupporting

confidence: 81%

“…Our objective was to further evaluate the efficacy of ondansetron in a randomized, placebo‐controlled, double‐blinded, cross‐over study, after promising results in a previous preliminary study 28 . Our study confirmed the results of the first open‐labeled study.…”

Section: Discussionsupporting

confidence: 58%

“…Our objective was to further evaluate the efficacy of ondansetron in a randomized, placebo-controlled, double-blinded, cross-over study, after promising results in a previous preliminary study. 28 The pathophysiological mechanisms of nausea are complex and still not completely understood, which makes appropriate pharmacological management challenging. The vestibular nuclei play a central role in the relay of vestibular information and are involved in the pathway for the induction of nausea in the tractus solitarius.…”

Section: Discussionmentioning

confidence: 99%

“…In vitro, ondansetron has high affinity and selectivity for 5‐HT3 receptors and antagonizes the effects of serotonin 27 . In a preliminary study of 16 dogs with vestibular disease, ondansetron significantly decreased the intensity of nausea within 2 hours after administration 28 …”

Section: Introductionmentioning

confidence: 99%

“…27 In a preliminary study of 16 dogs with vestibular disease, ondansetron significantly decreased the intensity of nausea within 2 hours after administration. 28 Our aim was to evaluate the efficacy and safety of ondansetron in dogs with vestibular syndrome using a randomized, placebo-controlled, double-blinded, crossover study. An additional aim was to assess the drug's effect on nausea objectively by measuring serum AVP concentrations pre-and post-administration.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Ondansetron in dogs with nausea associated with vestibular disease: A double‐blinded, randomized placebo‐controlled crossover study

Henze

Foth

Meller

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Nausea and emesis can be, among other signs, common manifestations of acute vestibular system dysfunction in dogs. Currently, antiemetic drugs, such as maropitant and metoclopramide, are used commonly, but do not appear to control nausea. A non‐placebo‐controlled preliminary study suggested good efficacy of 5‐HT3‐receptor antagonists, such as ondansetron, against nausea in dogs with vestibular syndrome. Objectives To assess and confirm the effect of ondansetron on behavior suggestive of nausea in dogs with vestibular syndrome. Animals Fourteen dogs with vestibular syndrome and clinical signs of nausea presented to a neurology service. Methods Placebo‐controlled, double‐blinded, crossover study. Behavioral assessment was performed hourly for 4 hours using an established numerical rating scale. The criteria salivation, lip licking, vocalization, restlessness, lethargy, and general nausea were scored. The occurrence of emesis was recorded. After scoring at T0 (pre‐dose) and T2 (2 hours post‐dose) either ondansetron (0.5 mg/kg) or placebo was injected IV. Two hours post‐dose, treatments were switched. Blood samples were collected to measure serum arginine vasopressin (AVP) concentration, which previously has been shown to correlate with clinical signs of nausea. Results Clinical resolution of nausea was observed 1 hour after administration of ondansetron, whereas serum AVP concentration decreased 4 hours after ondansetron administration. Conclusion and Clinical Importance Administration of ondansetron IV is beneficial for dogs with nausea secondary to acute vestibular syndrome. Ondansetron substantially and rapidly decreased clinical signs of nausea behavior and stopped emesis.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionsupporting

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Ondansetron in dogs with nausea associated with vestibular disease: A double‐blinded, randomized placebo‐controlled crossover study

Henze

Foth

Meller

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

Pharmacokinetics and anti‐nausea effects of intravenous ondansetron in hospitalized dogs exhibiting clinical signs of nausea

Sotelo

Shropshire

Quimby

et al. 2022

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The purpose of this study was to evaluate the pharmacokinetics of intravenous (IV) ondansetron in a population of hospitalized dogs exhibiting clinical signs of nausea. The causes of nausea included pancreatitis, gastroenteritis, endocarditis, chemotherapyinduced nausea, diabetes mellitus and ketoacidosis, acute kidney injury with aspiration pneumonia, pyometra, uroabdomen, neoplasia, and hepatopathy. Twenty-four dogs were randomly assigned to one of the following IV ondansetron protocols: 1 mg/ kg q12h, 0.5 mg/kg q12h, 1 mg/kg q8h, 0.5 mg/kg q8h. Serum was collected at 0, 0.25, 0.5, 1, 2, 4, 8, 16, and 24 h after the first dose, and nausea scores were recorded at multiple time points. Ondansetron and arginine vasopressin (AVP) concentrations were measured via high-performance liquid chromatography coupled to tandem mass spectrometry and ELISA, respectively. Noncompartmental pharmacokinetic modeling and dose interval modeling were performed. Ondansetron displayed linear pharmacokinetics. In the 0.5 mg/kg group, mean C max = 214 ng/ml, AUC 0-8h = 463 ng/ ml*h, and calculated half-life was 1.9 h. In the 1 mg/kg group, mean C max = 541 ng/ml, AUC 0-8h = 1057 ng/ml*h and calculated half-life was 1.6 h. Serum ondansetron concentrations were not significantly different between dogs that required rescue antinausea medication (non-responders) and dogs that did not require rescue therapy (responders). In total, 83.3% of patients in the 0.5 mg/kg q8h, 0.5 mg/kg q12h, and 1 mg/kg q8h groups had improvement in nausea scores. In total, 66.7% of patients in the 1 mg/kg q12h group had improvement in nausea scores. In total, 33% of patients had resolution of nausea in the 0.5 mg/kg q8h, 1 mg/kg q8h, and 1 mg/kg q12h groups, and 16% of patients had resolution of nausea in the 0.5 mg/kg q12h group. AVP concentrations were highly variable and did not correlate with nausea scores.Nausea scores significantly decreased regardless of dosage protocol. AVP was not a reliable biomarker of nausea in this group of dogs.

show abstract

The Use of Ondansetron for the Treatment of Nausea in Dogs With Vestibular Syndrome

Cited by 2 publications

References 48 publications

Ondansetron in dogs with nausea associated with vestibular disease: A double‐blinded, randomized placebo‐controlled crossover study

Ondansetron in dogs with nausea associated with vestibular disease: A double‐blinded, randomized placebo‐controlled crossover study

Pharmacokinetics and anti‐nausea effects of intravenous ondansetron in hospitalized dogs exhibiting clinical signs of nausea

Contact Info

Product

Resources

About